PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that it has obtained ANSM (French agency for the safety of […]
Other News
FineHeart Achieves Milestone for Its Miniaturized Heart Pump Technology With Successful Completion of 30-day Preclinical Study
The ICOMS device is the first destination therapy that restores natural heart pumping capacity This successful milestone is a major step towards first in human clinical trials BORDEAUX, France–(BUSINESS WIRE)–FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of […]
Cardiac Insight Increases Access to Lifesaving Wearable ECG AFib Detection Technology with Record Sales
Accelerating speed to diagnosis, allowing immediate access to patient ECG data, and enabling new revenue streams for physicians credited in rapid sales growth for leading ECG analysis platform BELLEVUE, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a healthcare innovator specializing in wearable cardiac sensors and automated electrocardiogram (ECG) analysis software that delivers highly […]
PleuraFlow Shown to Enable Improved Outcomes for Cardiac Surgery Patients in New Clinical Study Results
Reduction of Patient Complications After Heart Surgery Demonstrated with Use of the ClearFlow’s PleuraFlow ACT System IRVINE, Calif.–(BUSINESS WIRE)–ClearFlow, Inc., a medical device company based in Irvine, California, has announced positive clinical trial results presented at the 2020 Virtual Program of the Annual Eastern Cardiothoracic Surgical Society Conference (ECTSS) on […]
CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study. The brigHTN study is a Phase 2 clinical trial evaluating the blood pressure lowering effects of CIN-107, […]
Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure
MIAMI, Oct. 20, 2020 (GLOBE NEWSWIRE) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use […]
Study shows taking Entresto® as prescribed associated with lowering total cost of care by $6.7 million
Real-world findings helped in decision making to remove drug’s prior authorization EAGAN, Minn., Oct. 20, 2020 /PRNewswire/ — Sacubitril-valsartan (Entresto®) has been proven to decrease hospitalization and reduce death due to heart failure with reduced ejection fraction (HFrEF) also known as systolic heart failure. 1 According to a recent study by Prime Therapeutics LLC […]
Brain Scientific Appoints Stuart Bernstein as VP of Marketing
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) — via NewMediaWire ‒ Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, today announced the appointment of Stuart Bernstein as Vice President of Marketing. In this role, Bernstein will be responsible for Brain Scientific’s overall marketing strategy and efforts to strengthen the company’s market […]
3M™ Littmann® Stethoscopes and Eko Announce New Collaboration
Bringing together science, technology, and comprehensive solutions to redefine what’s possible in healthcare ST. PAUL‚ Minn. & OAKLAND, Calif.–(BUSINESS WIRE)–As the world of healthcare and its dependence on auscultation continues to evolve, digital technology is being introduced to meet the advancing demands of the industry. To meet these changing needs, 3M™ […]
OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent
OPTIMIZE Pivotal Study 1 Year Outcomes Announced at TCT Connect NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–The Svelte® Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study. Primary and secondary endpoint outcomes of the OPTIMIZE IDE study, designed […]



